TrialInflammopharmacology2026

Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions.

Feng Xiong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.